Meticulous Research®, a leading global market research company, has recently published a comprehensive report titled, ‘North America NGS Automation Market by Product (Workstations, Consumables), Sequencing Type (Whole Genome, Exome, Targeted Genome), Application (Drug Discovery, Diagnostics, Oncology), End User (Hospitals, Pharmaceutical, Diagnostic Labs) - Forecast to 2030.’

Download Sample Research PDF @ https://www.meticulousresearch.com/download-sample-report/cp_id=5736

This report provides in-depth insights into the North American Next-Generation Sequencing (NGS) automation market, forecasting a compound annual growth rate (CAGR) of 14% from 2024 to 2030. By the end of the forecast period, the market is expected to reach a value of $776.1 million. The growth of this market is driven by several factors, including the rising prevalence of cancer cases, the increasing demand for NGS automation in laboratories, and the growing need for streamlined and optimized workflows. Additionally, the expansion of pharmaceutical research and development (R&D) expenditures, coupled with rising healthcare investments, are expected to play a crucial role in shaping the market’s future.

NGS technology, known for its ability to quickly sequence large quantities of DNA and RNA, is increasingly being adopted for a wide array of applications such as clinical diagnostics, oncology, and drug discovery. This rapid adoption, along with strategic collaborations between vendors aimed at improving NGS library preparation protocols, is expected to create substantial growth opportunities. However, the high costs associated with NGS automation workstations are anticipated to be a key factor restraining the market’s growth to some extent.

Market Segmentation and Insights
The North America NGS automation market is segmented based on product type, sequencing type, application, end user, and geography. Let’s delve into each of these segments:

Product Segmentation:
The North America NGS automation market is primarily divided into two main categories: Workstations/Robotic Platforms and Reagents & Consumables.
1. Workstations/Robotic Platforms: The workstations and robotic platforms segment is expected to account for the largest market share in 2024. This growth is attributed to the numerous advantages of automating NGS processes, particularly in library preparation. Automation offers benefits such as increased efficiency, reduced turnaround times, lower per-sample costs, and improved reproducibility when compared to manual methods. These advantages are particularly significant in pharmaceutical and biotechnology companies, where drug discovery processes heavily rely on high-throughput screening and large-scale sequencing.
2. Reagents & Consumables: The reagents and consumables segment is also expected to experience growth, driven by the rising adoption of NGS technology in clinical diagnostics, oncology, and drug discovery applications. As more laboratories integrate automation systems, there is an increasing demand for high-quality reagents and consumables to support automated workflows.

Browse In Depth: https://www.meticulousresearch.com/product/north-america-ngs-automation-market-5736

Sequencing Type Segmentation:
The NGS automation market is further segmented by sequencing types, including Whole Genome Sequencing, Whole Exome Sequencing, Targeted Genome Sequencing, and Other Sequencing Types.
1. Whole Genome Sequencing (WGS): WGS is anticipated to dominate the market in 2024, driven by the increasing use of NGS technology for identifying novel drug targets and developing therapeutic techniques. WGS enables the comprehensive analysis of an individual’s entire genome, making it a powerful tool in precision medicine, especially for targeted therapies, gene therapies, and oligonucleotide therapies. The growing focus on personalized medicine and the development of treatments tailored to an individual’s genetic makeup further fuels the demand for WGS.
2. Whole Exome Sequencing (WES) and Targeted Genome Sequencing: Both of these segments are also poised for growth, although at a slightly lower rate compared to WGS. Exome sequencing, which focuses on the protein-coding regions of the genome, is gaining traction in various research and diagnostic applications. Targeted sequencing, on the other hand, is widely used for identifying specific mutations in genes linked to various diseases, including cancer.

Application Segmentation:
The North America NGS automation market is also divided into key applications, such as Drug Discovery, Clinical Diagnostics (including Reproductive Health, Oncology, and Infectious Disease Diagnostics), and other specialized applications.
1. Drug Discovery: The drug discovery segment is expected to hold the largest market share in 2024. NGS is increasingly used to identify novel drug targets and to develop therapies that are tailored to specific genes and proteins. These targeted therapies have revolutionized the treatment of diseases like cancer, making drug discovery a major application of NGS automation. The ability to rapidly sequence genomes and analyze large datasets has drastically accelerated the drug discovery process, making NGS an indispensable tool in the pharmaceutical industry.
2. Clinical Diagnostics: NGS is also playing a pivotal role in clinical diagnostics, especially in oncology, reproductive health, and infectious disease diagnostics. With its ability to detect genetic mutations and analyze complex genomic data, NGS has become an essential technology in diagnosing and understanding various diseases. The growing applications of NGS-based diagnostics, along with the rise in genetic disorders and cancer cases, are expected to contribute significantly to market growth.

End User Segmentation:
The end users of NGS automation systems are categorized into Pharmaceutical & Biotechnology Companies, Hospitals & Diagnostic Laboratories, Academic & Research Institutes, and Other End Users.
1. Pharmaceutical & Biotechnology Companies: This segment is expected to capture the largest share of the NGS automation market in 2024. The rise in pharmaceutical and biotechnology R&D expenditures, particularly in drug discovery and personalized medicine, is a key driver. NGS automation is helping companies reduce time and cost in drug development by allowing for the rapid analysis of vast genomic datasets.
2. Hospitals & Diagnostic Laboratories: As the demand for NGS-based diagnostics grows, hospitals and diagnostic laboratories are increasingly adopting NGS automation to streamline their workflows and improve accuracy in genetic testing. This adoption is being driven by the increasing prevalence of cancer, genetic disorders, and the overall growth of the healthcare sector.

Geographical Segmentation:
The report also highlights the performance of the NGS automation market across various countries in North America, with particular emphasis on the United States.
1. United States: The U.S. is expected to hold the largest share of the North America NGS automation market in 2024. Several factors contribute to this dominance, including the substantial R&D investments by the pharmaceutical and biotechnology sectors, the presence of leading NGS automation platform providers, and government initiatives supporting genomics research. Moreover, the growing awareness of NGS-based tests, along with the increasing prevalence of cancer and other genetic disorders, further bolsters the demand for NGS automation in the U.S. Additionally, favorable reimbursement scenarios in the U.S. healthcare system are also expected to encourage the adoption of NGS technology.
2. Canada: While Canada represents a smaller portion of the market, its NGS automation sector is expected to grow steadily due to rising healthcare investments and increasing collaborations between research institutions and biotechnology companies. The Canadian government’s support for genomics research also presents favorable market conditions.

Market Challenges and Opportunities
Despite the promising growth, the NGS automation market faces challenges, particularly the high cost of automation workstations. These high upfront costs may limit the adoption of NGS automation in some smaller laboratories or research institutions, particularly in emerging markets. However, as technology advances and economies of scale take effect, the prices of NGS automation systems are expected to decrease, facilitating broader market penetration.

On the opportunities front, the expanding applications of NGS technology in clinical diagnostics, personalized medicine, and drug discovery present vast growth prospects. Moreover, ongoing collaborations between vendors to enhance NGS technology and improve library preparation protocols are likely to foster innovation and accelerate market expansion.

Key Players in the North America NGS Automation Market
The report highlights several key players operating in the North America NGS automation market, including Agilent Technologies, Inc. (U.S.), Danaher Corporation (U.S.), Eppendorf AG (Germany), Hamilton Company (U.S.), PerkinElmer, Inc. (U.S.), Tecan Group Ltd. (Switzerland), BRAND GMBH + CO KG (Germany), Hudson Robotics (U.S.), SPT Labtech (U.K.), Thermo Fisher Scientific Inc. (U.S.), and F. Hoffmann-La Roche Ltd. (Switzerland). These companies are key players driving the market through their innovative NGS automation solutions and strategic partnerships.

Quick Buy – North America NGS Automation Market – Global Opportunity Analysis and Industry Forecast (2024-2030), Research Report: https://www.meticulousresearch.com/Checkout/75503538

Conclusion
The North America NGS automation market is poised for substantial growth over the next several years, driven by advancements in genomic technologies, increased research and development activities, and the growing prevalence of genetic disorders and cancer. As automation improves efficiency and reduces costs, the adoption of NGS technology is expected to expand rapidly across various applications, particularly in drug discovery and clinical diagnostics. The future outlook for the market remains positive, with significant opportunities for innovation, investment, and market expansion.

Contact Us:
Meticulous Research®
Email- [email protected]
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research